The Role of Lactobacillus Reuteri DSM 17938 Reducing Indirect Bilirubin Levels in Neonatal Hyperbilirubinemia

Abstract

Neonatal jaundice is a yellowish discoloration of the skin, conjunctiva, and sclera due to increased serum or plasma bilirubin in the neonatal period. This condition can cause parents' anxiety and increase the need to go to the hospital. In general, phototherapy was one of the therapeutic options to reduce neonatal hyperbilirubinemia with subsequent side effects such as dehydration, retinal damage, and bronze-baby syndrome. There is a need for further therapeutic options to treat neonatal hyperbilirubinemia with minimal side effects, and Lactobacillus was one of many options that have been proposed. This double-blind, randomized clinical trial was conducted to determine the role of Lactobacillus reuteri DSM 17938 to treat neonatal hyperbilirubinemia in conjunction with phototherapy.  In conclusion, administration of Lactobacillus reuteri DSM 17938 can reduce indirect bilirubin levels in neonatal hyperbilirubinemia faster compared to the group without intervention (p-value 0.000).